3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
57
Carcinoma, Ovarian Epithelial
28
Fallopian Tube Neoplasms
20
Uterine Cervical Neoplasms
17
Endometrial Neoplasms
17
Breast Neoplasms
13
Stomach Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
9
Prostatic Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Esophageal Neoplasms
7
Carcinoma, Renal Cell
7
Peritoneal Neoplasms
6
Melanoma
6
Uterine Neoplasms
4
Urinary Bladder Neoplasms
4
Small Cell Lung Carcinoma
4
Sarcoma
4
Pancreatic Neoplasms
4
Neoplasms
4
Head and Neck Neoplasms
4
Esthesioneuroblastoma, Olfactory
4
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Triple Negative Breast Neoplasms
3
Salivary Gland Neoplasms
3
Kidney Neoplasms
3
Brenner Tumor
3
Interventions
pembrolizumab
2
Nivolumab
2
Specimen Handling
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Immunotherapy
1
Imatinib Mesylate
1
Drug Therapy
1
Docetaxel
1
CTLA-4 Antigen
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Adenoid Cystic
×
Docetaxel
×
Gynecologic
×
Clear all
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled